Tuberculosis News and Research

Latest Tuberculosis News and Research

First Edition: June 30, 2014

Today's early morning highlights from the major news organizations, including an announcement coming today for a new VA secretary and expectations for a Supreme Court decision on the challenge to the health law's contraceptive mandate by two for-profit companies.

30 Jun 2014

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy.

28 Jun 2014

First step toward new drugs that can transcend antibiotic resistance issues

Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health.

28 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Research: TB infection among people taking corticosteroid pills may be underestimated

Tuberculosis infection among people taking corticosteroid pills may be underestimated, new research suggests.

26 Jun 2014

Computer analysis of family photos could help diagnose rare genetic disorders

Computer analysis of photographs could help doctors diagnose which condition a child with a rare genetic disorder has, say Oxford University researchers.

24 Jun 2014

FEI announces the sale of a complete correlative workflow to the University of Maastricht

FEI (NASDAQ: FEIC) announces the sale of a complete correlative workflow to the University of Maastricht. The systems will be installed at the University’s Institute of Nanoscopy, a new research facility that will use the high-resolution microscopes to understand the working mechanisms of protein complexes in an effort to develop new and improved treatment and prevention for disease, such as cancer and tuberculosis.

23 Jun 2014

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

When the body receives an injury to the skin, a signal is sent to the brain, which generates a sensation of pain.

20 Jun 2014

DNA sequencing does not reveal the pathogenicity of bacteria

While more and more genomic information is becoming available at a drastically increasing pace, the knowledge we can gain about how microorganisms interact with their surrounding, infect hosts and alter their molecular programs in accordance to changing environmental conditions remains widely not deducible from genomic data alone, the researchers from University of Southern Denmark claim.

19 Jun 2014

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher.

17 Jun 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder.

11 Jun 2014

Anthrax, brucellosis and bovine TB fail to receive official recognition, say researchers

Decades of neglect have allowed infectious diseases to devastate the lives of thousands of people in the developing world, a study reveals.

9 Jun 2014

New TB blood test could eliminate unnecessary treatment

A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50 per cent of those screened won't undergo unnecessary treatment due to false positives.

6 Jun 2014

Patients and families benefit from shorter TB treatment regimens

Shorter TB treatment regimens will reduce the out-of-pocket expenses incurred by both patients and their family members, who often act as the patients' guardians. In addition, shorter TB regimens may allow an earlier return to productive activities for patients and their families.

5 Jun 2014

UK makes £5.64M investment in most advanced crystallography technology

The UK's structural biology community will have access to the most advanced crystallography technology in the world thanks to a - £5.64M investment from UK research funders.

3 Jun 2014

Growing resistance to antibiotics demands a coordinated global response, say experts

Growing resistance to antibiotics and other drugs demands a coordinated global response on the same scale as efforts to address climate change, experts say.

23 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Disease-causing bacteria can linger in airplane cabins for days, says study

Disease-causing bacteria can linger on surfaces commonly found in airplane cabins for days, even up to a week, according to research presented at the annual meeting of the American Society for Microbiology.

21 May 2014

Chronic bystander viral impairs development of memory T cells

Studies of vaccine programs in the developing world have revealed that individuals with chronic infections such as malaria and hepatitis tend to be less likely to develop the fullest possible immunity benefits from vaccines for unrelated illnesses.

16 May 2014

Tuberculosis News and Research

Latest Tuberculosis News and Research

First Edition: June 30, 2014

Host-directed therapy: A new type of TB treatment

First step toward new drugs that can transcend antibiotic resistance issues

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Research: TB infection among people taking corticosteroid pills may be underestimated

Computer analysis of family photos could help diagnose rare genetic disorders

FEI announces the sale of a complete correlative workflow to the University of Maastricht

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

DNA sequencing does not reveal the pathogenicity of bacteria

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Anthrax, brucellosis and bovine TB fail to receive official recognition, say researchers

New TB blood test could eliminate unnecessary treatment

Patients and families benefit from shorter TB treatment regimens

UK makes £5.64M investment in most advanced crystallography technology

Growing resistance to antibiotics demands a coordinated global response, say experts

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Disease-causing bacteria can linger in airplane cabins for days, says study

Chronic bystander viral impairs development of memory T cells

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Tuberculosis News and Research

Latest Tuberculosis News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in